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Summary 
Interferon 3' (IFN-3")  interacts synergistically with bacterial lipopolysaccharide (LPS)  to induce 
transcription  of iNOS,  the isoform of nitric  oxide synthase whose activity is independent  of 
elevated  Ca  2+  and  exogenous  calmodulin.  To  define  a  cis-acting  element  mediating  IFN- 
3"-dependent synergy, we made deletions in iNOS promoter constructs fused to reporter genes, 
transfected RAW 264.7 macrophages, and treated the cells with IFN-3' and/or LPS. This analysis 
implicated the region from positions  -951 to  -911, a cluster of four enhancer elements known 
to bind IFN-3'-responsive transcription factors, including an interferon regulatory factor binding 
site (IRF-E) at nucleotides  - 913 to  - 923. Site-specific substitution of two conserved nucleotides 
within  IRF-E in the context of the full-length iNOS promoter ablated IFN-3"s contribution 
to synergistic enhancement of transcription.  Electromobility shift assays performed with a probe 
containing  IRF-E revealed the existence of a complex in nuclei of RAW 264.7 macrophages 
that was present only after treatment with IFN-3', which reacted specifically with anti-IRF-1 
immunoglobulin  G  and which included a species migrating  at 40-45 kD, consistent with the 
apparent  molecular weight of murine  IRF-1.  Thus,  the synergistic contribution  of IFN-3' to 
transcription  of iNOS in RAW 264.7 macrophages requires that  IRF-1 bind to ItLF-E in the 
iNOS promoter.  In conjunction with the work of Kamijo et al.  (Kamijo,  R.,  H.  Harada,  T. 
Matsuyama,  M. Bosland, J.  Gerecitano,  D.  Shapiro, J.  Le,  K.  S.  Im,  T.  Kimura,  S. Green et 
al. 1994. Science[Wash. DC]. 263:1612),  these findings identify iNOS as the first gene that requires 
IRF-1  for IFN-3'-dependent  transcriptional  regulation. 
N 
'itric oxide (NO) 1, a radical  gas, acts as an intercellular 
messenger in most mammalian  organs,  participating 
in vascular homeostasis,  neurotransmission, and defense against 
infectious agents (1). Three isoforms of NO synthase (NOS) 
have been cloned (2-4). The isoform expressed in the widest 
variety of cell types is termed iNOS because its activity is 
independent  of elevated Ca  2  + or exogenous calmodulin  (4, 
5). Activity of iNOS has been associated with tissue damage 
in arthritis,  nephritis,  insulitis,  and septic shock (6-10), leading 
to interest  in factors that  control its expression. 
Expression of iNOS generally requires exposure of cells 
to immune or inflammatory stimuli (1). This inductive phe- 
nomenon was first demonstrated with mouse peritoneal mac- 
1Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; 
EMSA, electrophoretic  mobility shift assay; GAS, "y-activated  site; iNOS, 
nitric oxide  synthase  whose  activity  is independent of exogenous  calmodulin 
and elevation of intracellular [Ca  2+ ] above the level in resting cells, the 
expression of which is usually  inducible; IRF, interferon regulatory  factor; 
IRF-E, IRF-binding element; ISREd/,, interferon-stimulated response 
element, downstream/upstream; NF-xB, nuclear factor for K  light chain 
in B lymphocytes; NO, nitric oxide. 
rophages treated with bacterial LPS, in which NO produc- 
tion was enhanced synergistically by the addition of IFN-3' 
(11, 12). Synergistic enhancement of NO production has sub- 
sequently been demonstrated in many types of myeloid, mesen- 
chymal, and epithelial cells exposed to two or more stimuli 
(13). That expression of iNOS is regulated largely at the tran- 
scriptional level  has  been formally demonstrated  in mouse 
macrophages (4), where it has also been shown that the syn- 
ergistic interaction between LPS and IFN-3' in the induction 
of iNOS is itself largely transcriptional  (14). 
Cloning of the promoter of the murine iNOS gene (15, 
16) has  opened a molecular route to the analysis  of iNOS 
induction. During induction of iNOS in mouse macrophages 
by LPS,  a protein complex containing  nuclear factor for ~c 
L chain in B lymphocytes (NF-KB) heterodimers (pS0/c-Rel 
and p50/RelA) binds to the downstream NF-xB site,  NF- 
KBd (17). On the other hand, the promoter region upstream 
from -  722 is necessary for IFN-3' to enhance synergistically 
the induction of iNOS by LPS (15,  16).  This upstream re- 
gion contains four copies of an IFN-3' response element (3" 
IRE), two copies of the 3"-activated site (GAS), and two copies 
of the IFN-stimulated response element (ISRE), designated 
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complementary nudeotide sequence of the ISREd core (Fig. 
1 A) closely matches a consensus sequence termed IFN regula- 
tory factor dement  (IRF-E)  (18). 
IRF-1 is an IRF-E binding protein (14) whose physiologic 
importance has been a matter of controversy (19-24). CD8 + 
lymphocytes were decreased in mice with a targeted disrup- 
tion of the IRF-1 gene (25). However, no specific gene was 
identified whose expression was directly affected by the lack 
of IRF-1.  Recently, Kamijo et al. (26) discovered that mac- 
rophages  from  IRF-1 ~176  mice  failed  to  accumulate  iNOS 
mRNA  after stimulation  with LPS in the presence or ab- 
sence of IFN-'y. However, it was not clear if IRF-1 controlled 
expression of iNOS directly or via the regulation of another 
gene. 
The present study establishes  that  the IR.F-E is required 
for IFN-3' to exert synergistic induction of iNOS transcrip- 
tion, and identifies IRF-1 as a major protein in IFN-3,-treated 
RAW 264.7 macrophages that binds directly to this element 
in the iNOS  promoter. 
Materials  and Methods 
Cell Culture.  The macrophage cell line RAW 264.7 (American 
Type Culture Collection, Rockville, MD) was  grown in RPMI 
1640 (JRH Biosciences, Lenexa, KS) supplemented with 10% fetal 
bovine serum (Hyclone Laboratories,  Logan, UT), 2 mM r-gluta- 
mine, and 200/~g/ml each of penicillin and streptomycin. 
Reagents.  Recombinant IFN-3' was a gift of Genentech (South 
San Francisco,  CA). LPS (from Escherichia coli Ol1:B4) was from 
Sigma Chemical Co. (St. louis, MO). Poly(dI-dC)-poly(dI-dC) was 
from Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Isotopes 
were from Amersham Corp. (Arlington Heights, IL). Purified rabbit 
IgG against purified recombinant murine IRF-1 was prepared by 
Teruaki Nomura and Heinz Ruffner and was kindly provided by 
Dr. Luiz Reis (University of Zurich, Zurich, Switzerland). Rabbit 
antiserum against  human STAT91, a kind gift of K. Shuai and J. 
Daruell (The Rockefeller University, New York, NY), cross-reacts 
with mouse STAT91 (Shuai,  K., personal communication). 
Plasmids.  Plasmid pIO.5iNOS-CAT was constructed by deleting 
the upstream region of the iNOS promoter (-1588 to -976) from 
the plasmid pliNOS-CAT (10) after a HindlII site was created at 
position -975 by PCR mutagenesis.  A 2-bp substitution (AA to 
GG, Fig.  1 B) was introduced into the IRF-E of the iNOS pro- 
moter cloned in plasmid  pUP1  (15) by oligonucleotide-directed 
mutagenesis  with single-stranded DNA. The SalI promoter frag- 
ment containing the generated mutation was subcloned into the 
pCAT-Basic vector (Promega Corp.,  Madison,  WI) to form the 
plasmid  pl(IRF'),  a  mutant  of pliNOS-CAT  (15). Two dual- 
reporter gene constructs, pl-hc and pl(IRF").luc,  were obtained 
by inserting the BgllI-BamHI fragment of pGL2-control vector 
(Promega Corp.), containing a SV40 promoter, a luciferase reporter 
gene, a splicing segment, and a polyadenyhtion signal, at the BamHI 
site of the plasmids  pliNOS.CAT and pl(IRb'~). 
Transient Transfection and Reporter Gene Assays.  Plasmid prepa- 
rations were used only if their content of LPS was calculated  to 
be <25 pg/ml at the concentrations used for transfection, based 
on assay of undiluted stocks by the chromogenic Limuhs assay 
(Whittaker Biomolecular, Walkersville,  MD).  RAW 264.7 cells 
were transfected and chloramphenicol acetyhransferase (CAT) ac- 
tivity assayed by TLC as described  (15). The luciferase assay was 
carded out as described by the manufacturer (Promega) and used 
to normalize the results  of the CAT assay. 
Oligonucleotides and Probes.  Single-stranded  oligonucleotides 
A 
NFkBu  GAS  ISRE  d 
*GGGGGATTTTCCCTCTCTCTGTTTGTTCCTTTTC~CTAACACTGTCAATATTTCACTTTCATAATGGAAAATTC 
CCCCCTA~AGGGAGAGAGAC~CP~a_GG~GGGGATTGTGACAGTTAT~.G~GTATTACCTTTT~G* 
-973  ISRE  u  IRF-E  -899 
DNA  probes 
for  E~ISA 
J  48  b.p.  -  probe  j 
I  IRFE/  ISRE d  I 
I  GAS/ISRE~  I 
B 
IRF-E consensus sequence: 
IRF-E sequence in iNOS promoter: 
mutation  in iNOS promoter IRF-E sequence: 
3 '  SYAAAGYSAAA(A)  G  -5' 
-  9 2 6  AATATTTCACTTTCATAA  -  9 0 9 
TTAT/~'I~._4~GTATT 
Figure  1.  DNA  sequence  of 
iNOS  promoter  fragments con- 
taining IRF-E site. (.4) Promoter  re- 
gion (-973 to  -899) containing 
putative binding sites for transcrip- 
tion  factors: NF-KB~ (17), GAS, 
IRF-E, and two ISRE sites: IS1LE~ 
and ISREd. The IRF-E site is indi- 
cated in bold. The positions for oli- 
gonucleotides used in EMSA are 
shown below. (B) IRF-E consensus 
sequence (18) compared  with IRF-E 
of iNOS promoter (bold). Boxed 
nucleotides  were mutated as shown. 
Y  =  C or T. S =  GorC. 
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otigomers below. The IRF-E site is underlined and mutations are 
italicized. These oligomers were filled in with Klenow fragment 
of E. coli DNA polymerase to obtain labeled probes or unlabeled 
competitors for electrophoretic mobility shift assays (EMSAs): 
48-bp oligomer: 
5' - TGTTTGTTCCTTTTCCCCTAACACTGTCAATATTTCACTTTCATAATG  - 3' 
IRF-E/ISREd: 
3'-GACAGTTATAAAGTGAAAGTATTAC-5' 
5'-CACTGTCAATATTTCAC-3' 
GAS/ISRE~: 
3'-GACAGTTATAAAGTGAAAGTATTA-5' 
5'-TGTTTGTTCCTTTTCCCCTAACA  -3' 
IRF-Em/ISREam: 
3,-GG.a,  AAAGGGGATTGTGAC-5' 
5'-CACTGTCAATATCCCAC  - 3' 
3' - GACAGTTATAGGGTGAAAGTATTA  - 5' 
EMSAs.  Binding reactions (10 #1 total) were performed by in- 
cubating 7.5/~g of nuclear extract prepared as described (27) with 
0.02 pmol of the DNA probe (,~200,000 cpm) in reaction buffer 
(20 mM Hepes, pH 7.9, I mM EDTA, I mM dithiothreitol), con- 
taining 4/~g of poly(dI-dC)-poly(dI-dC), for 30 min at room tem- 
perature. In competition assays, excess oligonucleotide competitor 
was preincubated with nuclear extract for 30 min at room temper- 
ature. In "supershift" assays, antibodies were added either before 
or after the binding reaction, as indicated. Incubation with anti- 
body was performed at 4~  for 60 min. For UV cross-linking, 
the probe was prepared with BrdU substituted for T, the binding 
reaction was scaled-up 10-fold and the cross-linking performed as 
described (17). 
Results 
The Region between - 975 to -  722 is Important for IFN-T's 
Contribution to Induction of the iNOS Promoter.  Comparison 
of pliNOS-CAT (containing the full-length iNOS promoter 
region -1588 to  +161) and p3ilVOS-CAT (-721 to  +161) 
revealed that the upstream portion (- 1588 to  - 722) of the 
iNOS promoter contributed to the synergistic action of IFN-3' 
with LPS for induction of the iNOS gene (17). More CAT 
constructs  were  derived  from  pliNOS-CAT  by  making 
progressive deletions from the 5' end up to -976. These con- 
structs were transfected into RAW 264.7 cells and CAT ac- 
tivity was measured 15 h after exposure to the cells to IFN- 
% LPS, both, or neither, plO.5iNOS-CAT, in which the pro- 
moter was deleted to - 975, displayed activity indistinguish- 
able from pliNOS-CAT.  That is, IFN-3' alone induced no 
CAT activity, but IFN-3' contributed synergistically to the 
CAT activity induced by LPS (data not shown). Thus, the 
region  -975 to  -722 contains elements important for the 
synergistic induction of iNOS by IFN-3' and LPS. 
Analysis of the promoter sequence in the region - 973 to 
-722 revealed the presence of five potential sites for binding 
of known IFN-q,-activated transcription factors.  Four of 
these-one GAS,  one IRF-E,  and two ISRE  (ISREu  and 
979  Martin  et al. 
ISREa) are clustered within the region  -951 to  -911 (Fig. 
1 A). An independent deletional analysis that was not presented 
was said to implicate the region  -1029  to  -913  (16). 
A Promoter Construct Bearing a Site-specific  Mutation in IRF-E 
Fails to Support Synergistic Activation by LPS and IFN-  T.  The 
induction of iNOS mRNA by IFN-3' and LPS is blocked 
by inhibition of protein synthesis (28-30). Therefore, among 
the candidate sites for IFN-3, action identified above, we fo- 
cused on IRF-E, because  it is the only one for which the 
IFN-y-induced intranuclear mobilization of binding factors 
is believed to depend on new protein synthesis. To test the 
role of the iNOS IRF-E, a site-specific mutation of two adja- 
cent nucleotides in IRF-E was generated in pliNOS-CAT 
to generate the plasmid pl(IRF  m) (Fig.  1 B). The positions 
mutated are conserved among known IRF-Es (18). A similar 
substitution in ISRE, an element closely related in sequence 
to IRF-E but which binds transcription factors distinct from 
IRF-1, also led to its functional inactivation (31). To deter- 
mine the effect of this mutation without a confounding effect 
of possible differences in the efficiency of transfection between 
the wild-type and mutant promoter constructs, we subcloned 
into  both  pliNOS-CAT  and  pI(IRF  ~)  an  independent 
.< 
< 
A  pl4ue 
B 
6 
2 
O  .  -,-  I  I 
0  0.1  1  10 
pl(IRFm).luc 
4 
2 
0  ~ 
0  0.1  1  10 
LPS (ng/ml) 
Figure  2.  IFN-'y-enhanced activation of wild-type but not IRF-E mu- 
tant iNOS promoter. CAT activity was determined in RAW 264.7 cells 
transfected with pl-/uc (A) and pl(IRF")-luc (B) constructs after 15 h of 
cell treatment with the indicated amounts of LPS with (m) or without 
([2]) IFN-3" (50 U/ml).  CAT activity was normalized for luciferase ac- 
tivity as described in Materials and Methods. In four such normalized ex- 
periments with LPS at 10 ng/ml, use of the wild-type promoter resulted 
in 3.35  _+ 1.4% acetylation (mean -+ SEM) with IFN-'y and 1.4 _+ 0.1% 
without IFN-3,, whereas use of the IRF-E mutant promoter resulted in 
1.03  +  0.1% acetylation with IFN-3' and 3.20  +  1.0% without IFN-3,. 
Results were qualitatively similar in two additional experiments using CAT 
reporter constructs without luciferase for normalization. reporter gene encoding luciferase  under the control of the 
constitutively  active SV40 promoter, giving rise to the plasmids 
pl-luc and pl(IRFm)-luc. Transfection of RAW 264.7  rnac- 
rophages with the latter plasmid preserved inducibility of  LPS, 
but the synergistic contribution of IFN-3, was abrogated. In 
fact, a modest suppressive  effect of IFN-q' on LPS-induced 
CAT expression was revealed  (Fig.  2). 
IFN-~/ Induces the Appearance of Nuclear Proteins that Bind 
the IRF-E in the iNOS Promoter.  We next performed EMSAs 
with extracts of nuclei isolated from RAW 264.7 cells after 
2 h of treatment with various stimuli. With a 48-bp  probe 
containing four putative binding sites for IFN-activated tran- 
scription factors (Fig. 1 A), two constitutive complexes were 
found in untreated cells  (designated A and c  in Fig. 3 A). 
Nuclear extracts from IFN-'y-treated cells contained an ad- 
ditional complex, termed B (Fig. 3 A). Complexes A and B 
were preserved but complex c was lost in EMSAs performed 
with a shorter probe consisting mostly of the IRF-E/ISREa 
sites. Reciprocally, complex c  was preserved  whereas com- 
plexes A and B were lost in EMSAs performed with a probe 
consisting mostly of the GAS/ISRE~ sites (Fig. 3 A). These 
results suggested that constitutively active nuclear protein(s) 
bind both sets of sites, but that IFN-q, activates the binding 
of protein(s) specifically to the IRF-E or ISREd site to form 
complex B (Fig. 3 A). Competition assays  demonstrated that 
complexes ^, B, and c each bound specifically in the pattern 
described above (Fig. 3 B). Moreover,  IFN-'y-inducible com- 
plex B was not bound to the probe containing the mutant 
IRF-E/ISREd site (Fig.  3 A). 
The IFN-9,-induced  Promoter-binding  Complex Contains  IRF-I 
Protein.  Nuclear  extracts  from  IFN-y-treated cells  were 
treated with specific antibodies against the two known tran- 
scription factors whose activity is regulated by IFN-'),  and 
that bind to GAS,  ISRE, or IRF-E sites in the promoters 
Figure  3.  Binding of proteins 
from nuclei  of RAW 264.7 cells to 
iNOS promoter  fragments.  (A) The 
binding reaction was  performed 
with nuclear extracts from cells 
treated for 2 h with or without the 
indicated stimuli at the concentra- 
tions shown  in Fig. 2. The reaction 
was carried out with oligonucleo- 
tide probes consisting  chiefly  of all 
four  binding  sites (lanes I--4), IRF- 
E/ISREa (lanes 5-8), GAS/ISRE~ 
(lanes 9-I2) or mutant IRF-E~/ 
ISREa  m  (lanes 13-I6). Positions  of 
complexes  A, B, and c are indicated 
by arrows. (B) The binding  reaction 
was carried  out in the absence  (lanes 
I--4) or presence  of  a 250-fold  molar 
excess of oligonucleotide  compe- 
titors  containing IRF-E/ISREa 
(lanes  5  and  6)  or  GAS/ISILEu 
(lanes 7 and 8) binding sites. The 
radiolabeled probe containing all 
four  sites  was used  for the reaction. 
Cells were treated as in A. 
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incubated in the absence (lanes I-4) or presence of preimmune  IgG (lane 
7 and 8) or specific  anti-IKF-1  IgG (lanes  5, 6, 9, and 10). IgG was added 
in a final  dilution  of 1:10 (750 ng/reaction)  or 1:250 (30 ng/reaction).  In 
lanes 6, 8, and 10 IgG was added  60 rain  before  the oligonucleotide,  whereas 
in lanes 5, 7, and 9 IgG was added 30 min after the oligonucleotide. 
of other genes, namely, STAT91 (32) and IRF-1 (19). Results 
were similar whether antibodies were added before or after 
nuclear proteins were allowed to bind to the oligonucleotide 
probes. Immune serum against STAT91 did not interfere with 
the formation of complexes a, B, or c  (data not shown). In 
contrast, when the extracts were treated with anti-IRF-1 IgG, 
complex e  disappeared.  In its place,  when relatively high 
Figure 5.  UV  cross-linking 
analysis  of  IFN-'y-inducible  com- 
plex. (2~p) Nuclear extract from 
RAW 264.7 cells treated with 
IFN-'y (50 U/ml) for 2 h was 
reacted  with the 48-bp probe  con- 
taining BrdU in the IKF-E in a 
scaled-up  EMSA.  (Bottom) The gel 
was irradiated  at 254 nm from 5 
cm for 60 min at 4~  The region 
corresponding to complex  B  was 
excised  and analyzed  by 10% SDS- 
PAGE followed by autoradiog- 
raphy (lane  2). The migration  of 
relative molecular weight stan- 
dards is indicated (lane I). 
amounts of IgG were used (750 ng/reaction), radioactive ma- 
terial was retained in the well (Fig. 4, lanes 5 and 6), whereas 
if 25-fold-less  IgG was used, radioactive material was dis- 
tributed between the well and upper part of the gel lane. 
Preimmune IgG at the same concentrations had no effect. 
This specific "supershift" demonstrated that complex s con- 
tains IRF-1 protein. UV cross-linking of the IFN-3,-induc- 
ible complex n  to the radiolabeled 48-pb  probe revealed  a 
heavily labeled protein migrating in SDS-PAGE at 40-45 kD, 
together with two faintly labeled species migrating at ~ 105 
and 205  kD  (Fig.  5). 
Discussion 
Many cell types have the capacity to produce large amounts 
of NO after exposure to immune or inflammatory stimuli. 
This may reflect a beneficial role of iNOS in mediating some 
of the antiviral actions of IFN-~ (33).  However, the same 
enzyme is demonstrably autotoxic (6-10). Thus, its expres- 
sion is likely to be highly regulated. Indeed, iNOS is regu- 
lated in the rate of its transcription (14-17),  the stability and 
rate of translation of its mRNA, and the stability of the pro- 
tein (34), as well as by undefined, nondegradative posttrans- 
lational means (35). The focus here on synergistic induction 
of transcription of iNOS does not exclude that the same stimuli 
may interact synergistically at posttranscriptional levels as well. 
Induction of iNOS by LPS in RAW 264.7  cells involves 
the binding of NF-KB heterodimers p50/c-Rel and p50/RelA 
to the NF-KB  site  at  -85  to  -75  in the iNOS promoter 
(17). Here we have marshalled complementary evidence with 
regard to the action of IFN-'y in the same macrophage-like 
cell line. However, the extent of the synergistic interaction 
between LPS and IFN-~,  in transfected cells was restricted 
(Fig.  2;  and ref.  11,  see Fig. 3)  compared to what is seen 
with untransfected cells (14). Whereas we are not certain what 
causes  this  restriction,  we  emphasize that  it  is  extremely 
difficult to prepare plasmid DNA for transfection from E. coli 
host cells without trace contamination by LPS. If mouse mac- 
rophages are pretreated with LPS in the picogram per mil- 
liter concentration range,  they express  markedly decreased 
levels ofiNOS mKNA when subsequently exposed to IFN-y 
(36). Thus, preexposure to traces of LPS at the time of trans- 
fection may have blunted the subsequent inductive response. 
Within the limitations of a transfection-based reporter gene 
model, the evidence presented here establishes that the IKF-E 
at -913 to -923 and its binding of IKF-1 are critical molec- 
ular  determinants  of the  action  of IFN-'y on  the  iNOS 
promoter. 
IKF-1 is activated by viral infection, double-stranded  P,  NA, 
IFN-ot, and IFN-3' (20,  37),  and serves as a transcriptional 
activator for type I IFN genes as well as for a number of 
IFN-inducible genes, such as MHC class I (e.g., H-2K  b) and 
2'-5' oligoadenylate synthase (23, 24). However, all these genes 
are also regulated in part if not predominantly  by other tran- 
scription factors, such as interferon-stimulated gene factor 3 
(ISGF3)  and gamma-activating factor (GAF), as such genes 
are induced normally in fibroblasts from IKF-1  ~176  mice (25). 
In contrast, the inability of macrophages from these animals 
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ulation with IFN-3, in the presence or absence of LPS (26) 
demonstrated that IRF-1 plays a critical physiologic role in 
the induction of iNOS. Kamijo et al. (26) showed further 
that a nucleotide element from the iNOS promoter could 
compete with the binding of recombinant IRF-1 to an ideal- 
ized IR.F-E concatemer. These authors, however, studied nei- 
ther the iNOS promoter itself, nor transcriptional  control 
proteins from nuclei of IFN-3~-treated cells. The present work 
establishes that  IFN-'y mobilizes  intranuclear IKF-1,  that 
IRF-I binds to the IR.F-E in the iNOS promoter, and that 
these events are necessary for IFN-'y to enhance the iNOS 
promoter's transcriptional activity. Together with the results 
of Kamijo et al. (26), our study points to iNOS as the first 
specific gene for whose direct transcriptional  regulation by 
IFN-'y, IRF-1 is found to be indispensable. 
However,  the role of IRF-1 in induction of iNOS may 
not be limited to its interaction with IRF-E in the iNOS 
promoter.  In the studies of Karnijo et al. (26), IRF-1 ~176  mac- 
rophages failed to express iNOS not only when stimulated 
with IFN-% but also when stimulated with LPS alone. Thus, 
IRF-1 is likely to participate,  directly or indirectly,  in the 
cycloheximide-sensitive assembly of the LPS-activated tran- 
scription factor complex on NF-KBd which we have shown 
is involved in LPS-induced transcription of iNOS (17). For 
example, IR.F-1 may regulate transcription of the unidentified 
115-kD protein that participates in the formation of this com- 
plex (17). 
Site-specific mutation of IRF-E within the context of the 
full-length iNOS promoter/enhancer region demonstrated the 
importance of this site in the response of iNOS to IFN-% 
In addition,  mutation of IRF-E revealed the action of a si- 
lencer, in that LPS-induced expression of reporter gene ac- 
tivity was even higher than with the wild-type promoter. 
A likely candidate for the silencer element is IRF-E itself, 
and candidate inhibitory factors binding thereto are IRF-2 
(38) and IFN consensus sequence binding protein (39), which 
act as constitutive repressors in other systems. Moreover, mu- 
tation of IRF-E converted IFN-3;s action on transcription 
from stimulatory to suppressive, suggesting the operation of 
an IFN-3,-activated silencing mechanism operating elsewhere 
than via wild-type IRF-E. 
The inference that IRF-E supported the IFN-'y-induced 
binding of nuclear proteins  was confirmed by EMSA anal- 
ysis. The DNA probe containing IRF-E/ISREa sites formed 
two distinct complexes with nuclear proteins, ^ and B (Fig. 
3 A). Both complexes were specific in that their formation 
was prevented  by excess  unlabeled oligonucleotide. While com- 
plex ^ was constitutive,  complex B appeared only after ex- 
posure of the cells to IFN-% The substitution of two adja- 
cent  nucleotides  conserved  in  the  IKF-E  prevented  the 
formation of complex B, corroborating the functional anal- 
ysis of the full-length promoter/enhancer  with the mutation. 
A similar band pattern was reported with the IRF-E from 
the promoter of the H-2K  b MHC class I gene, whose IRF-E 
conforms to the iNOS IRF-E in 10/11 nucleotides (40). Like- 
wise, a 2-bp substitution in the H-2K  b IRF-E blocked for- 
mation of the IFN-y-inducible complex (although different 
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positions were substituted than in iNOS), and IKF-1 (termed 
IBP1) was identified in the IFN-'y-inducible complex (40). 
In the iNOS promoter, even  though both complexes A and 
B formed on the same site (IRF-E/IRSEa), we found no 
higher order complex corresponding to ^ and B, implying 
a competition between two binding factors. This interpreta- 
tion is consistent with the observation that treatment with 
LPS and IFN-3~ usually led to an increase in complex B at 
the expense of complex ^  (Fig. 3 A, compare lanes 2 and 
4,  or  6  and  8).  Complex  c  formed  constitutively  on 
GAS/ISREu,  reminiscent  of the  results  of in  vivo  foot- 
printing analysis of the overlapping GAS/ISRE sites in the 
promoter of guanylate binding protein (41). Complex c did 
not make a joint complex with ^ and/or B (Fig. 3). Thus, 
the binding of complexes, ^, B, and c each appeared to be 
mutually exclusive. 
Two observations supported the conclusion that complex 
B contained IRF-1-a supershift in EMSA with specific  anti- 
IRF-1 antibody (Fig. 4), and UV-cross-linking  of the 48-bp 
IRF-E-containing probe to complex B protein(s)  (Fig. 5). 
The protein predominantly cross-linked to the labeled DNA 
migrated with an apparent molecular mass of 40-45 kD. The 
molecular mass of mouse IRF-1 deduced from its cDNA is 
37.3 kD, but recombinant mouse IRF-1 migrated at 48 kD 
in SDS-PAGE (42). The two cross-linked polypeptides we 
observed migrating at `o105 and ,o205 kD are reminiscent 
of the two species of >97 kD that copurified with human 
ISGF2 (22). These may be additional components of com- 
plex B whose contact with DNA was more limited than that 
of IRF-1.  Alternatively, the higher relative molecular mass 
species may represent cross-linked oligomers of IRF-1 or con- 
taminants  of the binding reaction. 
The identification  of IRF-E as critical to the impact  of 
IFN-y on the iNOS promoter does not exclude a possible 
role of candidate IFN-3~-response sites downstream of posi- 
tion  -975, including seven ISREs, three GAS sites, and an 
X box (15). To determine whether IRF-E alone mediates the 
positive effects of IFN-'y on the iNOS promoter would re- 
quire mutating or deleting each of these elements. 
Now that sites in the iNOS promoter have been identified 
for the transcriptional effects of  both LPS and IFN-'y, it may 
be possible to define the precise mechanism of their interac- 
tion. For example, one or more proteins in the NF-KB-con- 
taining complex forming at  -85 to -76, may make contact 
with protein(s)  in the IRF-l-containing complex at  -913 
to  -923.  Such an interaction between NF-~B and ISGF2 
(IRF-1) underlies the synergistic activation of the promoter 
of the HLA-B7 MHC class I gene by TNF and IFN-'y (43). 
However, whereas the NF-~B site and the IRF-E on the HLA- 
B7 promoter are only 10 bp apart,  the cognate sites in the 
iNOS promoter are separated by 828 bp. The bending of the 
iNOS promoter that would presumably be required for in- 
teraction of NF-~B- and IRF-E-binding proteins may be facili- 
tated by the intervening regions with potential Z-DNA con- 
formation (15). 
The benign phenotype of uninfected mice with lifelong 
IRF-1 deficiency (25) raises the possibility that a temporary 
state of functional inactivation of IRF-1 might be tolerable 
and Induction of Nitric Oxide Synthase in uninfected individuals with inflammatory disorders. Inhi- 
bition of IRF-1 binding would be expected to block expres- 
sion of iNOS without interfering with expression of the neural 
and endothelial isoforms of NOS.  Development of IRF-1 
blockers could complement the screening for iNOS-specific 
substrate analog inhibitors, an approach that has yet to bear 
fruit. 
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